US Pharma MarketingSanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline.
Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue
Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analy Sanofi has stopped a phase 3 autoimmune clinical trial early after an interim analysis found the therapy was “unlikely to provide sufficient efficacy.” The setback eliminates one opportunity for a key late-phase program and continues the “bumpy ride” for Sanofi’s pipeline. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards…
Source: FierceBiotech